TY - JOUR
T1 - Profound retinal ischaemia after ranibizumab administration in an eye with ocular ischaemic syndrome
AU - Kofoed, Peter Kristian
AU - Munch, Inger Christine
AU - Larsen, Michael
N1 - © 2009 The Authors. Journal compilation © 2009 Acta Ophthalmol.
PY - 2009
Y1 - 2009
N2 - Abstract. Purpose: To report the result of ranibizumab administration in an eye with ocular ischaemic syndrome. Methods: Fluorescein angiography, ocular pneumoplethysmography and retinal vessel calibre measurement. Results: An 85-year-old man with ocular ischaemic syndrome demonstrated vision loss, retinal vessel calibre constriction and profound retinal ischaemia after intravitreal ranibizumab. Conclusion: We advise against the use of intravitreal vascular endothelial growth factor inhibitors in eyes with ocular ischaemic syndrome.
AB - Abstract. Purpose: To report the result of ranibizumab administration in an eye with ocular ischaemic syndrome. Methods: Fluorescein angiography, ocular pneumoplethysmography and retinal vessel calibre measurement. Results: An 85-year-old man with ocular ischaemic syndrome demonstrated vision loss, retinal vessel calibre constriction and profound retinal ischaemia after intravitreal ranibizumab. Conclusion: We advise against the use of intravitreal vascular endothelial growth factor inhibitors in eyes with ocular ischaemic syndrome.
U2 - 10.1111/j.1755-3768.2009.01612.x
DO - 10.1111/j.1755-3768.2009.01612.x
M3 - Journal article
C2 - 19832734
SN - 1755-375X
VL - 88
SP - 808
EP - 810
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
IS - 7
ER -